This study focuses on the discovery of protein biomarkers for the early diagnosis of gastric cancer and the development of corresponding detection methods. By employing advanced mass spectrometry-based proteomic technologies, the investigators conducted an in-depth analysis of a large cohort of clinical samples to identify specific protein biomarkers capable of accurately distinguishing gastric cancer patients from healthy individuals. The findings from this research are expected to facilitate the development of novel non-invasive or minimally invasive diagnostic approaches, thereby improving early detection, enhancing patient prognosis, and increasing survival rates.
Male or female, aged ≥18 and ≤95 years.
Histopathologically confirmed gastric cancer, as defined by the 2024 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer.
No prior anti-tumor treatment (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Availability of complete clinicopathological data and follow-up information.
History of prior malignancy or cancer treatment.
Presence of concurrent malignancies of other types.
Inability to tolerate gastroscopy.